Clinical Trials Arena on MSN
Eli Lilly’s Taltz-Zepbound combo scores in late-stage PsA study
These results tout the potential of the combination as the new standard of care (SoC) for PsA patients with comorbid obesity.
Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the novel TOGETHER-PsA open-label Phase 3b ...
Combination therapy with ixekizumab and tirzepatide bested monotherapy with ixekizumab alone in both psoriatic arthritis and ...
INDIANAPOLIS, Aug. 8, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the availability of a new, citrate-free formulation of Taltz ® (ixekizumab) injection 80 mg/mL. The new ...
The TOGETHER-PsA study shows that combining ixekizumab with tirzepatide leads to significantly better psoriatic arthritis ...
Eli Lilly said combining Taltz and Zepbound improved arthritis symptoms and drove meaningful weight loss, outperforming Taltz ...
Please provide your email address to receive an email when new articles are posted on . A citrate-free formulation of Taltz injection for patients is now available following its FDA approval earlier ...
(RTTNews) - Eli Lilly and Company (LLY) on Monday said its new formulation of Taltz (ixekizumab), which was approved by the FDA in May this year, is being made available across the U.S. The company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback